NCT02956265

Brief Summary

Actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the Northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. The surgeon in charge of such lesions' removal (i) some actinic keratosis adjoining carcinoma to be resected therefore causing the problem of functional areas damaging (eyelids, lips, etc.) or (ii) numerous actinic keratosis localized away from carcinoma (photo-carcinogenesis field) faces the issue of clinical evaluation of such lesions: which ones will spontaneously regress (it is supposed to be the case for 20 % of such lesions);which ones will remain and which ones will develop into invasive carcinomas ? A non-invasive, non-traumatic, automated and real-time help for the clinical diagnosis orientation of such skin lesions could help improving diagnosis accuracy of the medical practitioner's visual inspection:

  • In terms of sensitivity in order to potentially decrease the number of actinic keratosis evolving towards invasive carcinoma,
  • In terms of specificity in order to potentially decrease useless resections and reduce resection margins and therefore reduce scars surface.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
142

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 3, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 7, 2016

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 25, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 25, 2021

Completed
Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

4.5 years

First QC Date

November 3, 2016

Last Update Submit

April 21, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Optical spectroscopy's diagnostic validity for the 4 histological classes discrimination

    day 1

Secondary Outcomes (3)

  • Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between in situ carcinoma (ISC) and invasive carcinoma (InvC).

    day 1

  • Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between 2 classes of actinic keratosis (AK) of clinical relevance: AK characterized by a "low" versus a "high" invasiveness risk

    day 1

  • - Sensitivity and specificity of optical spectroscopy for discriminating the é molecular classes of actinic keratosis: AK characterized by a "low" versus a "high" invasiveness risk.

    day 1

Study Arms (1)

Patients - Suffering from carcinomatous or polymorphous skin

EXPERIMENTAL
Device: bimodal optical spectroscopy

Interventions

an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra

Patients - Suffering from carcinomatous or polymorphous skin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults, and
  • Autonomous: enjoying full citizenship rights and full mental abilities, and
  • Affiliated to a social security system, and
  • Suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure.

You may not qualify if:

  • Carcinomatous or polymorphous skin lesions that require day admission, or
  • Carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or
  • Naevomatous skin lesions and related skin pathologies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHR Metz Thionville

Metz, 57085, France

Location

Related Publications (3)

  • Zghal A., Fauvel C., Kupriyanov V., Elsen T., Khairallah G., Blondel W., Amouroux M. Adv. Biomed. Clin. Diagn. Surg. Guid. Syst. XXI. SPIE; 2023. Human skin phototype and apparent age classification based on machine learning methods of autofluorescence and diffuse reflectance spectroscopic data acquired in vivo; pp. 60-64.

    RESULT
  • Blondel W., Delconte A., Khairallah G., Marchal F., Gavoille A., Amouroux M. Spatially-resolved multiply-excited autofluorescence and diffuse reflectance spectroscopy: spectrolive medical device for skin in vivo optical biopsy. Electronics. 2021;10:243. doi: 10.3390/electronics10030243.

    RESULT
  • Elsen T, Fauvel C, Khairallah G, Zghal A, Delconte A, Kupriyanov V, Blondel W, Amouroux M. A dataset of optical spectra and clinical features acquired on human healthy skin and on skin carcinomas. Data Brief. 2024 Feb 6;53:110163. doi: 10.1016/j.dib.2024.110163. eCollection 2024 Apr.

Study Officials

  • Grégoire Khairallah

    g.khairallah@chr-metz-thionville.fr

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 2016

First Posted

November 7, 2016

Study Start

October 1, 2016

Primary Completion

March 25, 2021

Study Completion

March 25, 2021

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations